J&J's Janssen Seeks FDA OK of Twice-Yearly Schizophrenia Treatment
November 02 2020 - 9:04AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on
Monday said it filed for U.S. Food and Drug Administration approval
of a six-month dose of paliperidone palmitate for the treatment of
adults diagnosed with schizophrenia.
The drug maker said the indication, if approved, would make
paliperidone palmitate the first and only long-acting injectable
schizophrenia treatment with a twice-yearly dosing regimen.
Janssen already markets paliperidone palmitate in a three-month
regimen as Invega Trinza and in a monthly dose as Invega Sustenna.
Janssen said the new regimen is intended for use only after
patients have been stabilized on a shorter acting formulation of
paliperidone palmitate, with the goal of administering fewer
injections.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 02, 2020 08:49 ET (13:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
